We are live on ! Find out more
AVAI

Atlas Venture Associates IX Portfolio holdings

AUM $11.8M
1-Year Est. Return 58.35%
This Fund
S&P 500
This Quarter Est. Return
+30.24%
1 Year Est. Return
-58.35%
3 Year Est. Return
-89.8%
5 Year Est. Return
-87.69%
10 Year Est. Return
AUM
$106M
AUM Growth
+$19.6M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
7
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 96.07%
2 Technology 2.38%
3 Communication Services 1.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NTLA icon
1
Intellia Therapeutics
NTLA
$1.52B
$27.6M 25.92%
1,615,321
SURF
2
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$22.2M 20.82%
4,645,453
SYBX
3
DELISTED
Synlogic
SYBX
$20.1M 18.91%
176,798
SPRO icon
4
Spero Therapeutics
SPRO
$68.9M
$17.6M 16.57%
1,376,968
COGT icon
5
Cogent Biosciences
COGT
$7.21B
$14.8M 13.86%
840,384
CBLK
6
DELISTED
Carbon Black, Inc. Common Stock
CBLK
$2.53M 2.38%
181,273
SNAP icon
7
Snap
SNAP
$9.62B
$1.66M 1.55%
150,160

Similar funds

Atlas Venture Associates IX's Q1 2019 Portfolio in Review

As of Q1 2019, Atlas Venture Associates IX held 7 positions worth $106M, up 23% from $86.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2019: portfolio turnover was 0%. Atlas Venture Associates IX opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Communication Services.

  • Atlas Venture Associates IX's ten largest holdings make up 100% of its $106M portfolio in Q1 2019.
  • Atlas Venture Associates IX opened 0 new positions and closed 0 in Q1 2019.
  • Atlas Venture Associates IX's portfolio value rose 23% quarter-over-quarter to $106M.

Based on Atlas Venture Associates IX's 13F filing for Q1 2019, filed 13 May 2019.